S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Urgent Warning (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Urgent Warning (Ad)
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Urgent Warning (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Urgent Warning (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Urgent Warning (Ad)
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Urgent Warning (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Urgent Warning (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Urgent Warning (Ad)
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Urgent Warning (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Urgent Warning (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Urgent Warning (Ad)
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Urgent Warning (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
NYSE:NVRO

Nevro - NVRO Stock Forecast, Price & News

$32.46
+1.64 (+5.32%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$30.58
$32.52
50-Day Range
$30.17
$39.79
52-Week Range
$28.75
$78.90
Volume
642,935 shs
Average Volume
535,349 shs
Market Capitalization
$1.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.30

Nevro MarketRank™ Forecast

Analyst Rating
Hold
1.91 Rating Score
Upside/​Downside
55.0% Upside
$50.30 Price Target
Short Interest
Bearish
8.45% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.43) to ($1.78) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

635th out of 1,005 stocks

Surgical & Medical Instruments Industry

62nd out of 102 stocks


NVRO stock logo

About Nevro (NYSE:NVRO) Stock

Nevro Corp. engages in the development of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes the senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.

Receive NVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter.

NVRO Stock News Headlines

StockNews.com Begins Coverage on Nevro (NYSE:NVRO)
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
Nevro Full Year 2022 Earnings: EPS Beats Expectations
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
4 MedTech Stocks Set to Outpace Q3 Earnings Estimates
What 4 Analyst Ratings Have To Say About Nevro
See More Headlines
Receive NVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter.

NVRO Company Calendar

Last Earnings
2/16/2023
Today
3/26/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
1,087
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$50.30
High Stock Price Forecast
$95.00
Low Stock Price Forecast
$31.00
Forecasted Upside/Downside
+55.0%
Consensus Rating
Hold
Rating Score (0-4)
1.91
Research Coverage
11 Analysts

Profitability

Net Income
$3 million
Pretax Margin
1.05%

Debt

Sales & Book Value

Annual Sales
$406.36 million
Book Value
$9.14 per share

Miscellaneous

Free Float
34,540,000
Market Cap
$1.15 billion
Optionable
Optionable
Beta
0.83

Key Executives

  • D. Keith GrossmanD. Keith Grossman
    Chairman, President & Chief Executive Officer
  • Bryan Hix
    Vice President-Commercial Operations
  • Roderick H. MacLeod
    Chief Financial Officer
  • David Caraway
    Chief Medical Officer
  • Christopher Christoforou
    Vice President-Technical Operations













NVRO Stock - Frequently Asked Questions

Should I buy or sell Nevro stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last twelve months. There are currently 3 sell ratings, 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVRO, but not buy additional shares or sell existing shares.
View NVRO analyst ratings
or view top-rated stocks.

What is Nevro's stock price forecast for 2023?

11 brokers have issued twelve-month price objectives for Nevro's stock. Their NVRO share price forecasts range from $31.00 to $95.00. On average, they expect the company's stock price to reach $50.30 in the next twelve months. This suggests a possible upside of 55.0% from the stock's current price.
View analysts price targets for NVRO
or view top-rated stocks among Wall Street analysts.

How have NVRO shares performed in 2023?

Nevro's stock was trading at $39.60 at the beginning of 2023. Since then, NVRO stock has decreased by 18.0% and is now trading at $32.46.
View the best growth stocks for 2023 here
.

When is Nevro's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our NVRO earnings forecast
.

How were Nevro's earnings last quarter?

Nevro Corp. (NYSE:NVRO) posted its quarterly earnings results on Thursday, February, 16th. The medical equipment provider reported ($0.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.05. The medical equipment provider had revenue of $113.84 million for the quarter, compared to the consensus estimate of $113.70 million. Nevro had a net margin of 0.74% and a negative trailing twelve-month return on equity of 36.24%. The business's revenue for the quarter was up 10.8% compared to the same quarter last year. During the same quarter last year, the company earned ($0.86) EPS.

What guidance has Nevro issued on next quarter's earnings?

Nevro issued an update on its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $445.00 million-$455.00 million, compared to the consensus revenue estimate of $449.24 million.

What is D. Keith Grossman's approval rating as Nevro's CEO?

9 employees have rated Nevro Chief Executive Officer D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

What is Nevro's stock symbol?

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Who are Nevro's major shareholders?

Nevro's stock is owned by a number of institutional and retail investors. Top institutional investors include Norges Bank (3.58%), ArrowMark Colorado Holdings LLC (3.53%), Fred Alger Management LLC (3.34%), Millennium Management LLC (2.60%), Principal Financial Group Inc. (2.16%) and Geode Capital Management LLC (1.77%). Insiders that own company stock include D Keith Grossman, Elizabeth H Weatherman, Kashif Rashid, Kevin C Oboyle, Leslie Stretch, Michael F Demane, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends
.

How do I buy shares of Nevro?

Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nevro's stock price today?

One share of NVRO stock can currently be purchased for approximately $32.46.

How much money does Nevro make?

Nevro (NYSE:NVRO) has a market capitalization of $1.15 billion and generates $406.36 million in revenue each year. The medical equipment provider earns $3 million in net income (profit) each year or ($0.01) on an earnings per share basis.

How many employees does Nevro have?

The company employs 1,087 workers across the globe.

How can I contact Nevro?

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The official website for the company is www.nevro.com. The medical equipment provider can be reached via phone at (650) 251-0005 or via email at ir@nevro.com.

This page (NYSE:NVRO) was last updated on 3/27/2023 by MarketBeat.com Staff